Neurological Disorders

Neurology Service, University Hospital Arnau de Vilanova, Lleida, Spain

Publications

• Case Report   
  Alemtuzumab-Induced Inflammatory Bowel Disease in a Multiple Sclerosis Patient
  Author(s): José Vicente Hervás García*, Gisela Torres-Vicente, Cristina González-Mingot, Anna Gil-Sánchez, Lara Nogueras, Silvia Peralta, María José Solana and Luis Brieva
  
  Introduction: Alemtuzumab produces a total depletion and posterior repopulation of T and B cells. Autoimmunity is an important adverse event of this drug. In recent years, other autoimmune diseases, different to thyroid, kidney and platelets alterations have been described. Clinical Case: We present one case of alemtuzumab-treated multiple sclerosis patient who develops ulcerative colitis after two cycles of alemtuzumab. Conclusion: To our knowledge, no cases have been published in the literature, which relate alemtuzumab with the development of ulcerative colitis. The different kinetics in B and T cells repopulations and the change in the gut microbiota induced by alemtuzumab or by changes in diet to prevent listeriosis, could increase the risk of developing this autoimmune phenomenon... Read More»
  DOI: 10.37421/2329-6895.2020.8.421

  Abstract HTML PDF